Lurbinectedin is a medication used for the treatment of metastatic small cell lung cancer (SCLC) in patients who have already received chemotherapy [3]. According to the drug's label, the most common side effects of lurbinectedin include fatigue, low white blood cell count, low platelet count, anemia, increased liver enzymes, increased creatinine, and increased glucose [3]. In clinical trials, 51% of patients experienced a decrease in their white blood cell count, with 10% experiencing a severe decrease [3]. It is important to note that white blood cells are a vital component of the immune system, responsible for fighting infections and diseases. Therefore, a decrease in white blood cell count can increase the risk of infections and other complications [2]. Patients taking lurbinectedin should be monitored closely for any signs of infection and have their blood counts checked regularly [2]. In conclusion, lurbinectedin can cause a decrease in white blood cell count, which can increase the risk of infections and other complications. Patients taking lurbinectedin should be monitored closely for any signs of infection and have their blood counts checked regularly.

Sources:
[2] Zepzelca.com. (n.d.). Side Effects of ZEPZELCA (lurbinectedin) for Small Cell Lung Cancer. Retrieved August 24, 2021, from https://www.zepzelca.com/zepzelca-side-effects/
[3] FDA. (2020). Zepzelca Prescribing Information. Retrieved August 24, 2021, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf